High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment
- PMID: 30711145
- PMCID: PMC6353816
- DOI: 10.1016/j.ijid.2018.10.021
High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment
Abstract
Objectives: To investigate the reasons for the high prevalence of epilepsy (>6%) discovered in 2015 in the Aketi health zone in the north of the Democratic Republic of the Congo.
Methods: Persons with epilepsy (PWE) diagnosed in a door-to-door survey in 2015 were traced and re-examined in 2017 by a neurologist. Confirmed PWE were paired with matched controls. For onchocerciasis assessment, children 7-10 years old were tested for IgG4 Onchocerca volvulus (OV16) antibodies, a rapid epidemiological mapping of onchocerciasis (REMO) study was performed, and ivermectin coverage was investigated.
Results: Forty-three (61.4%) previously diagnosed PWE were traced; the neurologist confirmed the epilepsy diagnosis in all of them. The overall OV16 positivity rate was 64.5%. Poor ivermectin coverage (55.9%) and a high prevalence of onchocercal nodules (>70%) were observed. The prevalence of epilepsy was 5.7% in Aketi rural town, with nine PWE (13.8%) experiencing head nodding seizures. A case-control study showed that PWE had lower body weight and higher ivermectin coverage in 2017 than healthy controls.
Conclusions: The high prevalence of epilepsy in the Aketi health zone, despite 14 years of community-directed treatment with ivermectin (CDTI), was found to be associated with high onchocerciasis transmission and low ivermectin use. An awareness programme to increase ivermectin coverage and the introduction of a bi-annual CDTI programme should be considered.
Keywords: Case–control; Epilepsy; Focus group discussion; Incidence; Ivermectin; Onchocerciasis; Prevalence; Stigma.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures



Comment in
-
Onchocerciasis associated epilepsy-A question of causality.Int J Infect Dis. 2019 Feb;79:185-186. doi: 10.1016/j.ijid.2019.01.044. Int J Infect Dis. 2019. PMID: 30711144 Free PMC article. No abstract available.
-
Epidemiological evidence concerning the association between onchocerciasis and epilepsy.Int J Infect Dis. 2019 May;82:77-78. doi: 10.1016/j.ijid.2019.03.015. Epub 2019 Mar 15. Int J Infect Dis. 2019. PMID: 30885705 No abstract available.
References
-
- Agresti A. 2nd ed. John Wiley and Sons Ltd.; New Jersey: 2003. Categorical data analysis. p. 202.
-
- Boussinesq M., Pion S.D., Demanga N., Kamgno J. Relationship between onchocerciasis and epilepsy: a matched case-control study in the Mbam Valley, Republic of Cameroon. Trans R Soc Trop Med Hyg. 2002;96:537–541. - PubMed
-
- Burnham G. Onchocerciasis. Lancet. 1998;351:1341–1346. - PubMed
-
- Casis S. El Sindrome Epileptico y sus reaciones con Onchocercosis. Boletin de Salubridad e Higiene. 1938:1.